146 results on '"Etra, Aaron"'
Search Results
2. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
3. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
4. A Day 14 Endpoint for Acute GVHD Clinical Trials
5. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
6. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
7. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
8. Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical Committee
9. Effective treatment of low-risk acute GVHD with itacitinib monotherapy
10. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
11. Flares of Acute Graft-Versus-Host Disease (GVHD): A Mount Sinai Acute GVHD International Consortium (MAGIC) Analysis
12. Ibrutinib for Therapy of Steroid-Refractory Chronic Graft Vs. Host Disease: A Multicenter Real-World Analysis
13. The Mount Sinai Acute Gvhd International Consortium (MAGIC) Model: An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease (GVHD)
14. The MAGIC Algorithm Probability Predicts Treatment Response and Long-Term Outcomes to Second-Line Therapy for Acute Gvhd
15. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
16. Acute Graft‐versus‐Host Disease
17. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin
18. Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease
19. The utility of biomarkers in acute GVHD prognostication
20. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
21. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant
22. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
23. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease
24. De Novo Late Acute Gvhd: Incidence, Outcomes, and Impact of Biomarkers Compared to Classic Acute Gvhd
25. REPOGRAMING OF THE INTESTINAL IMMUNE CELL COMPARTMENT DEFINES THE RESPONSE TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN CROHNS DISEASE
26. Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy
27. SARS-CoV-2 infection associated with aplastic anemia and pure red cell aplasia
28. Mo1537: COMBINATION AUTOLOGOUS STEM CELL TRANSPLANTATION AND VEDOLIZUMAB FOR REFRACTORY CROHN’S DISEASE
29. Pathogenic Germline Variants in Multiple Myeloma
30. Prognostic Value of Elafin in Acute Graft-Versus-Host Disease
31. P-063: Pathogenic germline variants in hereditary cancer genes in patients with Multiple Myeloma
32. Abstract 868: Heritable cancer mutations in multiple myeloma
33. A Case of Rare Autoimmune Pancytopenia Due to Graves’ Disease
34. 274 AUTOLOGOUS STEM CELL TRANSPLANT MAY “RESET” NOT ONLY THE IMMUNE SYSTEM BUT MICROBIOME STRUCTURE AND FUNCTION IN PATIENTS WITH CROHN'S DISEASE
35. Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease
36. 32 - De Novo Late Acute Gvhd: Incidence, Outcomes, and Impact of Biomarkers Compared to Classic Acute Gvhd
37. Death of Woman with peripartum influenza B virus infection and necrotizing pneumonia
38. The MAGIC Algorithm Probability (MAP) Is a Validated Response Biomarker of Treatment for Acute Graft-Versus-Host Disease
39. The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease
40. Thyroid Cancer
41. Bulletin
42. Comparison of Gvhd Biomarker Algorithms for Predicting Lethal Gvhd and Non-Relapse Mortality
43. Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease
44. Evaluating the safety of emicizumab in patients with hemophilia A
45. The MAGIC Algorithm Probability Predicts Long-Term Outcomes and Treatment Response to Second-Line Therapy for Acute Gvhd
46. A Day 14 Endpoint for Acute Gvhd Clinical Trials
47. Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study
48. Rethinking clinical trial design: maximizing the results from each clinical trial participant
49. Abstract 3849: Analysis of the mutation rate in T lymphoblastic leukemia cell lines
50. Tu2029 Recent Causes of Hepatocellular Carcinoma in a U.S. Urban Medical Center
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.